CLINICAL_TRIALS
withdrawal
· 2016-04-25
Clinical Trial Update: Brimonidine Tartrate for the Treatment of Injection Related Erythema [Phase 4]
Summary
A Phase 4 study evaluating brimonidine tartrate for injection-related erythema in relapsing-remitting multiple sclerosis has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 4 | Status: WITHDRAWN